gretel
22 Apr 2015
Re: Excellent presentation last night Brief notes from last night's presentation - apologies if anything written down/understood incorrectly: Sales should be up to $7.2m this year, with breakeven during the period, and ending with approx.$10m cash (i.e almost 50% of the m/cap). AKR can produce $50m of sales from their existing facilities, so there's no need for material capital expenditure. Heparin test - the price of AKR's Heparin test is to be INCREASED from May 1st, due to the huge savings for hospitals - 10 new sales reps are each opening 3 new hospital/customer accounts per month, each selling $30k per annum, which I calculate to be $10.8m revenues per annum once a year's selling is up and running - there should be one or two further Chinese orders this year Cholesterol test is perfect for Australia given distances/flying doctors etcf, and has achieved $900,000 of unbudgeted sales 5 products currently on the market, growing soon to 11Future products include (1) breath test for lung cancer, (2) test for type 1 diabetics, at 73% margins (this is AKR's lowest margin test!), (3) chlamydia test, to be perfected this summer after clinical trials. AKR's great advantage is that clinical trials only take a few months and cost relatively little. The diabetes test will be launched in China and USA this year. AKR already have a Chinese facility. I think he said the asthma test is this year too. There's no competition for the heparin and other breath tests (except the alcohol test in Europe).
gretel
22 Apr 2015
Excellent presentation last night Good to see 5,000 shares bought first thing this morning at 320p.Hopefully a reaction to last night's very good presentation by Ray Akers at Finncap (organised by Sharesoc), which reinforced my positive opinion about the company.More later.
gretel
20 Apr 2015
Good press coverage Nice coverage in last week's Independent:[link] drug company boosted by marketing deal One Alternative Investment Market company hoping to buck the general malaise on the junior market is Akers Biosciences, which will today announce a deal to begin marketing one of its flagship treatments in Britain and eight other European countries. Akers, which has a dual Aim and Nasdaq listing, has developed a pioneering new test that can rapidly detect whether patients have a potentially fatal allergy to heparin, the blood thinning drug routinely used in hospitals around the world. The test is already in use in the US healthcare systems but Akers will now begin selling it far more widely across Europe, the Middle East and Africa. The potential for the test is enormous – while millions are prescribed heparin, as many as 5 per cent of them develop an allergy to the product. Patients undergoing serious heart surgery or major orthopaedic procedures are regarded as particularly vulnerable to such problems."
gretel
13 Apr 2015
RNS re new distributors The infrastructure is certainly being put in place...once the sales follow through then the current tiny m/cap (almost wholly backed up by the cash pile anyway) will be extremely cheap imo:[link] AgreementsAkers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers" or the "Company"
, a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, has added six new distributors to market its rapid tests for heparin]induced thrombocytopenia ("HIT" in nine additional countries within Europe, the Middle East and Africa (EMEA). The Company has signed multi-year distribution agreements for PIFA Heparin/PF4 Rapid Assay products with Pathway Diagnostics Ltd, covering Great Britain; ACCUSCIENCE Ireland Ltd, covering Ireland and Northern Ireland; Tokra Medikal Tic Ltd Sti, covering Turkey; LabPro d.o.o, covering Serbia, Montenegro, Macedonia, Bosnia and Herzegovina; AVL Sofia Ltd, covering Bulgaria; and MASTERLAB SARL, covering Morocco. Akers has developed the only U.S. and E.U. cleared rapid test to detect a potentially fatal allergy to the widely used blood thinner, heparin. This clinical syndrome known as HIT reverses heparin's intended therapeutic effect and transforms it into a clotting agent. Patients suffering HIT are at risk of developing limb- and life-threatening complications, so the rapid diagnosis provided by the Company's Heparin/PF4 devices is paramount to effective, clinical decision making. Millions of patients are exposed to heparin around the world each year and between 1% and 5% of those patients receive a HIT diagnosis. The largest at-risk populations are patients undergoing major cardiac or orthopedic surgical procedures. "As sales of our rapid tests for HIT continue to rise in the U.S. we are actively seeking to roll out the marketing to other countries around the world," said Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman of the Board. "These additional distribution partnerships add to our expanding global footprint which now exposes the Company's flagship test to 20 non-U.S. markets including China," continued Dr. Akers. "Key to growing the international footprint is partnering with distributors with the right networks and experience to drive sales - in some cases in countries where there is no established procedure for testing for HIT," added Nicolas Daurel, Vice President, Sales and Marketing for EMEA. "We are confident that our international partners have these credentials and look forward to supporting their strategies.""
gretel
07 Apr 2015
Higer price in the USA AKR still performing well and at around 310p in the USA, compared to 275p in the UK.The CEO is presenting in London on 21st April...hopefully he'll have news flow to promote:[link]
Chard Nick
06 Apr 2015
Re: Opened strongly in the USA Hopefully get a good reaction on AIM - although I somehow doubt it!!
gretel
02 Apr 2015
Opened strongly in the USA Up 13% in the USA to $4.86 on the open, or around 325p.
gretel
02 Apr 2015
Terrific news today If AKR can sell into the US Government then other customers and markets will fall like dominoes:[link] Inc is "the world’s premier equipment, procurement, and support solutions specialist to the military, law enforcement, first responders, and the defense industry".....[link]
Chard Nick
23 Mar 2015
Jam tomorrow?? IMHO Akers is one of those companies which seem to promise a lot but when it comes to results they just don't seem to deliver.Granted that revenues are increasing, but I want to see some profits before too long! Not much to ask is it??Still holding, and hoping...
Chard Nick
18 Mar 2015
SP Increase I was wondering why, but I have just found a new presentation on the Akers website. Also results due on 23rd March.DYOR!!
gretel
26 Jan 2015
RNS - new European patent Nice....[link] "European Patent Granted for Akers' Rapid Blood Separation Technology Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers", a leading designer and manufacturer of rapid diagnostic screening and testing products, announces that the European Patent Office has issued a patent surrounding the Company's novel blood separator technology and method of separating a fluid fraction from whole blood (the "Technology". Akers was granted U.S. patent protection for the Technology in 2011. The Technology, developed and wholly owned by Akers, enables rapid blood cell separation of small volumes of whole blood, including those obtained from finger stick samples. utilizing the Technology, serum or plasma samples are extracted within 30-90 seconds and are ready for immediate analysis. contrast, conventional methods of blood cell separation are labor-intensive and time consuming, taking 30-120 minutes, and typically involving blood collection and laboratory personnel as well as electrically-powered centrifuges and other specialized equipment. The Technology, which further accelerates the rate at which a test result is obtained, is marketed by Akers under the brand name seraSTAT® and forms a key component of the Company's PIFA product range (Akers' proprietary platform for rapidly detecting or measuring specific proteins or other substances through their properties as antigens or antibodies). In addition to seraSTAT®'s incorporation within some of the Company's own diagnostic tests, Akers intends to license its proprietary blood separator Technology to third parties seeking to accelerate their own testing procedures by facilitating the blood cell separation process as a component of their test. "We believe the Company's blood separator Technology has a wide range of potential applications and we are actively seeking potential commercialization partners and licensees in both Europe and the U.S.," said Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman of the Board. "This Technology can make blood cell separation dramatically quicker and less resource-intensive than traditional methods - with significant potential advantages related to cost savings, staff efficiency, and the ability to perform certain diagnostic tests in the field versus lab environments," continued Dr. Akers."
gretel
06 Jan 2015
New interview with CEO Good to see the share price moving up again today - there doesn't seem to be much stock around given that a single buy caused a tick up, whilst a sell achieved a good premium to the bid price.If AKR achieve the numbers in this interview then the share price should move a long way forward from here imo, especially considering the current $10.2m cash pile against the £12.8m m/cap."5 Jan 2015 "ORLANDO, Fla., Jan. 5, 2015 (GLOBE NEWSWIRE) -- RedChip Companies, Inc. today announced that "The RedChip Money Report: Small Stocks Big Money"(TM) television program host Dave Gentry interviewed Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman of Akers Biosciences (AKER). During the interview, Dr. Akers provides insight into the Company's current value, growth prospects, and overall opportunity.The interview is now available online at: [link] Capital has an $11 per share price target on Akers Biosciences, which currently trades at 1.26x book value at $3.70 per share. During the interview, Dr. Akers reconfirms the Company's 2014 revenue guidance of $4 million to $5 million and forecasts 2015 revenues of $7.2 million to $10 million. Akers Biosciences is expected to reach profitability once it reaches $8.8 million in annual sales."[link]
gretel
05 Jan 2015
News:US approves AKR alcohol test Dated 3 Jan 2015:"Approved Prearrest and Evidential Breath Testing Devices CONFORMING PRODUCTS LIST OF ALCOHOL SCREENING DEVICESAkers Biosciences, Inc., Thorofare, New Jersey Breath Alcohol xx .02 Detection System.88 The Breath Alcohol xx .02 Detection System consists of a single-use disposable breath tube used in conjunction with an electronic analyzer that determines the test result. The electronic analyzer and the disposable breath tubes are lot specific and manufactured to remain calibrated throughout the shelf-life of the device. This screening device cannot be used after the expiration date.[link] "Prearrest breath testing devices approved under this authority may be used by police officers, waterways patrolmen and officers enforcing the Vehicle Code, the Fish and Boat Code and the Game and Wildlife Code in conducting preliminary determinations of the alcohol content of blood of persons suspected of driving, boating, hunting or furtaking while under the influence of alcohol. Officers and patrolmen use these devices to assist them in determining whether or not a person should be placed under arrest for violation of 75 Pa.C.S. § 3802 (relating to driving under influence of alcohol or controlled substance), for violation of 30 Pa.C.S. § 5502 (relating to operating watercraft under influence of alcohol or controlled substance), for violation of 34 Pa.C.S. § 2501 (relating to hunting or furtaking prohibited while under influence of alcohol or controlled substance) or for any other criminal offense under the Vehicle Code, the Fish and Boat Code or the Game and Wildlife Code which involves operating a vehicle or boat, hunting or furtaking while under the influence of alcohol."
gretel
05 Jan 2015
200% upside per new analyst report 2 Jan 2015 - Bright Outlook and New Products on the Way Prompt Analyst Report of Akers Bioscience Issued by BrokerBank Securities:[link] for 2015 is projected at $10.5m with a profit of $1m......"Target price for AKER is estimated at $11.80. The target price is based on the current P/S multiple of 5.57x (ttm) and an estimated revenue of 10.5M or $2.12 per share. The target price is well above today’s trading price of $4.15 leading to a buy recommendation for Aker. Today’s price is considered an attractive entry point considering that AKER is trading just above the book value (1.26x), has no debt, has significant cash in their balance sheet and is generating revenue from its current product lines and has several new product lines launching in FY2015.Summary & ConclusionAker Bioscience Inc. has much to smile about in the upcoming fiscal year. The PIFA Heparin PF4 Rapid Assay product line has been very successful in the US and has now been approved for distribution in Europe (press release Dec 18). With several more product lines nearing distribution stages, the outlook for FY 2015 is nothing but positive. Revenue is expected to double estimates of FY2014 and share price is estimated at $11.80."
gretel
31 Dec 2014
US price mugh higher than UK price It's also worth noting that the current price on the NASDAQ is $3.99, or around 254p - quite a lot higher than the current 227p UK price, so perhaps a buying opportunity for UK buyers:[link]
